Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 24, 2026, 5:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,142 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Type 2 Diabetes Patients Clear all
Recruiting No phase listed Observational

PRimary IndividualiZed Evaluation of Cardiovascular Events in Patients With Diabetes Mellitus Using hemoTAG

NCT06567795
View directory record Official record
Conditions
Diabetes Mellitus Type 2, Cardiovascular Diseases, Coronary Artery Disease, Cerebrovascular Disease, Peripheral Artery Disease
Interventions
Hemotag
Device
Lead sponsor
Aventusoft, LLC.
Industry
Eligibility
40 Years and older
Enrollment
189 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
West Palm Beach, Florida
Source: ClinicalTrials.gov public record
Updated Aug 22, 2024 · Synced Jul 24, 2026, 5:50 AM EDT
Terminated Phase 4 Interventional

Patient Preference of h-Patch vs. Pen or Needle/Syringe as Insulin Administration Device

NCT00453934
View directory record Official record
Conditions
Type 1 Diabetes, Type 2 Diabetes
Interventions
h-Patch
Device
Lead sponsor
Valeritas, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 5, 2007 · Synced Jul 24, 2026, 5:50 AM EDT
Completed Phase 4 Interventional Results available

U-500R Insulin In Type 2 Diabetes With Severe Insulin Resistance Via Omnipod

NCT00606034
View directory record Official record
Conditions
Type 2 Diabetes, Insulin Resistance
Interventions
U-500 Insulin delivered by Omnipod (disposable insulin pump)
Drug
Lead sponsor
Mountain Diabetes and Endocrine Center
Other
Eligibility
18 Years to 75 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Asheville, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 5, 2014 · Synced Jul 24, 2026, 5:50 AM EDT
Not yet recruiting Not applicable Interventional

Group Emotion-Focused Behavioral Intervention for Diabetes Distress/A1c in T2D.

NCT06912737
View directory record Official record
Conditions
T2DM (Type 2 Diabetes Mellitus)
Interventions
Group Emotion Focused Behavioral Intervention (G-EFBI), Group - With Every Heartbeat is Life (G-WEHL)
Behavioral
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 5, 2025 · Synced Jul 24, 2026, 5:50 AM EDT
Completed Not applicable Interventional

Peers LEAD Plus Healthy Living With Diabetes (HLWD)

NCT04857411
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Peers LEAD plus HLWD
Behavioral
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
20 Years to 90 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 13, 2022 · Synced Jul 24, 2026, 5:50 AM EDT
Completed No phase listed Observational

Estimation of Malignancy Rates Within Humedica Patient Populations Sampled to be Representative of Liraglutide Initiators and LEADER™ Trial Participants

NCT02608853
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
No treatment given
Other
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
Not listed
Enrollment
9,999 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 19, 2015 · Synced Jul 24, 2026, 5:50 AM EDT
Completed Phase 3 Interventional Results available

A Study Assessing Saxagliptin Treatment in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise

NCT00374907
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Saxagliptin, Placebo, Metformin (blinded), Metformin (open-label)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
3
States / cities
San Diego, California • Baton Rouge, Louisiana • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 6, 2015 · Synced Jul 24, 2026, 5:50 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Linagliptin (BI 1356) in Black/African Americans With Type 2 Diabetes With a MTT Sub-study

NCT01194830
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Linagliptin, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 80 Years
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
93
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 76 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2014 · Synced Jul 24, 2026, 5:50 AM EDT
Completed Phase 4 Interventional Results available

Transition From Basal/Bolus to Once-weekly Subcutaneous Semaglutide and Basal Insulin in Patients With T2D

NCT04538352
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Semaglutide, Insulin Degludec, Insulin aspart
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 17, 2025 · Synced Jul 24, 2026, 5:50 AM EDT
Completed Not applicable Interventional

Latinos Understanding the Need for Adherence

NCT02955238
View directory record Official record
Conditions
Atherosclerosis, High Blood Pressure, Type 2 Diabetes Mellitus, Heart Disease, Hypercholesterolemia
Interventions
Special Intervention
Behavioral
Lead sponsor
San Diego State University
Other
Eligibility
40 Years and older
Enrollment
587 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Nov 3, 2016 · Synced Jul 24, 2026, 5:50 AM EDT
Completed Phase 3 Interventional

Impact of Gastric Bypass Surgery on Risk of CVD in Type 2 Diabetes Mellitus

NCT00444392
View directory record Official record
Conditions
Obese Patients, Type 2 Diabetes Mellitus
Interventions
Calorie controlled diabetic diet for the control patients
Behavioral
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 60 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 20, 2016 · Synced Jul 24, 2026, 5:50 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Vildagliptin in Combination With Glimepiride in Patients With Type 2 Diabetes

NCT00099944
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
vildagliptin, Glimepiride, LAF237 placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
515 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated May 6, 2012 · Synced Jul 24, 2026, 5:50 AM EDT
Completed Phase 3 Interventional Results available

A Study in Participants With Type 2 Diabetes Mellitus

NCT01064687
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
LY2189265, Exenatide, Placebo, Metformin, Pioglitazone
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
978 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
78
States / cities
Goodyear, Arizona • Phoenix, Arizona • Cathedral City, California + 75 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2015 · Synced Jul 24, 2026, 5:50 AM EDT
Completed Not applicable Interventional

Peer Coaching for Low-Income Patients With Diabetes in Primary Care

NCT01040806
View directory record Official record
Conditions
Diabetes Type 2
Interventions
Usual care, Health coaching
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 20, 2022 · Synced Jul 24, 2026, 5:50 AM EDT
Active, not recruiting Not applicable Interventional

Weight Loss Clinical Decision Support

NCT05198765
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Obesity
Interventions
BMI-CDS
Behavioral
Lead sponsor
HealthPartners Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
10,120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 9, 2025 · Synced Jul 24, 2026, 5:50 AM EDT
Completed Phase 2 Interventional

Safety, Tolerability, and Efficacy Study of MB07803 Administered to Patients With Type 2 Diabetes Mellitus

NCT00458016
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
MB07803, Placebo
Drug
Lead sponsor
Ligand Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
25
States / cities
Los Angeles, California • Walnut Creek, California • Miami, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2011 · Synced Jul 24, 2026, 5:50 AM EDT
Completed Phase 3 Interventional

A Study of the Safety, Tolerability and Effect on Glycemic Control of Taspoglutide Versus Insulin Glargine in Insulin Naive Type 2 Diabetic Patients Inadequately Controlled With Metformin Plus Sulphonylurea.

NCT00755287
View directory record Official record
Conditions
Diabetes Mellitus Type 2
Interventions
insulin glargine, metformin, taspoglutide
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,072 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
74
States / cities
Phoenix, Arizona • Searcy, Arkansas • Concord, California + 63 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2016 · Synced Jul 24, 2026, 5:50 AM EDT
Completed Phase 1 Interventional Results available

Multiple Dose Study Of PF-04937319 In Patients With Type 2 Diabetes

NCT01272804
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, NIDDM
Interventions
PF-04937319, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
4
States / cities
Miami, Florida • South Miami, Florida • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 31, 2017 · Synced Jul 24, 2026, 5:50 AM EDT
Terminated Phase 4 Interventional Results available

CARAT: Canagliflozin vs. Placebo for Post Bariatric Patients With Persistent Type 2 Diabetes

NCT02912455
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Obesity
Interventions
canagliflozin, Placebo (for canagliflozin)
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
20 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 19, 2020 · Synced Jul 24, 2026, 5:50 AM EDT
Withdrawn Phase 3 Interventional

A Study to Evaluate ITCA 650 Compared to Sitagliptin for the Treatment of Type 2 Diabetes

NCT01455909
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
ITCA 650 60 mcg/day, sitagliptin
Drug
Lead sponsor
Intarcia Therapeutics
Industry
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Hayward, California
Source: ClinicalTrials.gov public record
Updated Dec 24, 2012 · Synced Jul 24, 2026, 5:50 AM EDT
Completed Phase 3 Interventional

An Open-Label Study Examining the Long-Term Safety of Exenatide Given Twice Daily to Patients With Type 2 Diabetes Mellitus

NCT01876849
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
exenatide
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
30 Years to 75 Years
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Renton, Washington
Source: ClinicalTrials.gov public record
Updated Feb 23, 2015 · Synced Jul 24, 2026, 5:50 AM EDT
Completed Phase 1Phase 2 Interventional

A 6 Week Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of GK1-399 in Type 2 Diabetes

NCT01474083
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
GK1-399 (formerly TTP399), Placebo
Drug
Lead sponsor
vTv Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
11
States / cities
Little Rock, Arkansas • Chula Vista, California • DeLand, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2013 · Synced Jul 24, 2026, 5:50 AM EDT
Completed Not applicable Interventional

Continuous Glucose Monitoring, Contingency Management, and Motivational Interviewing for Patients With Type 2 Diabetes in Kansas City

NCT06374186
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Behavioral Intervention with financial rewards and coaching, Control
Behavioral
Lead sponsor
University of Missouri, Kansas City
Other
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Jul 24, 2026, 5:50 AM EDT
Completed Phase 4 Interventional

Comparison of Insulin Glargine and NPH Human Insulin in Progression of Diabetic Retinopathy in Type 2 Diabetic Patients

NCT00174824
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Insulin glargine
Drug
Lead sponsor
Sanofi
Industry
Eligibility
30 Years to 70 Years
Enrollment
1,024 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 26, 2009 · Synced Jul 24, 2026, 5:50 AM EDT